Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
KD Pharma Group
Bioggio, Ticino, Switzerlandkdpharmagroup.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
The company has commercialized highly purified Omega 3 APIs globally. It also runs late-stage clinical trials using lipid-based technologies targeting FAP, UC, and COVID 19. No detailed trial results are published in the provided sources.
- Therapeutic areas
- OtherGastroenterologyOncologyInfectious Diseases
- Modalities
- Small moleculeLipid-based therapy (notably Omega‑3 fatty acids)Softgel finished dosage forms
- Industry
- Biotech
02
Partnerships
Not specifically listed; works with global pharma/nutritional companies as CDMO partner.
Beyond the preview
Go deeper on KD Pharma Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KD Pharma Group.